Price | 1W % | 1M % | 3M % | 6M % | 1Y % | YTD % |
|---|---|---|---|---|---|---|
-- | -- | -- | -- | -- | -- | -- |
AI Generated Qualitative Analysis
Your time is precious, so save it. Use AI to get the most important information from the business.
Learn about Neurogene Inc.
Neurogene Inc. News
May 16, 2025 - businesswire.com
Neurogene Announces Evidence-Based Monitoring and Treatment Intended to Reverse Rare Hyperinflammatory Syndrome Associated with High-Dose AAV
May 9, 2025 - businesswire.com
Neurogene Reports First Quarter 2025 Financial Results and Highlights Recent Updates
Apr 28, 2025 - businesswire.com
Neurogene Announces Upcoming Oral Presentation on Monitoring and Treatment to Reverse Rare Complication of High Dose Gene Therapy at the ASGCT Annual Meeting
Apr 2, 2025 - businesswire.com
Neurogene Announces Peer-Reviewed Publication Demonstrating Gene Therapy Candidate NGN-401 with EXACT™ Technology Regulates Transgene Expression in Preclinical Models of Rett Syndrome
Neurogene Inc. Quantitative Score
About Neurogene Inc.
Neurogene Inc. develops life-changing genetic medicines for patients and their families affected by neurological diseases. Its product candidate includes NGN-401, an investigational AAV9 gene therapy for the treatment of Rett syndrome; and NGN-101 to treat neuronal ceroid lipofuscinosis subtype 5 batten disease. The company is headquartered in New York, New York.
Neurogene Inc. Earnings & Revenue
What’s This Company Really Worth? Find Out Instantly.
Warren Buffett’s go-to valuation method is Discounted Cash Flow (DCF). Our tool makes it effortless — no spreadsheets, just answers in a few clicks.
Neurogene Inc. Financials
Table Compare
Compare NGNE metrics with: | |||
|---|---|---|---|
Earnings & Growth | NGNE | None | |
EPS (TTM) YoY Growth | -- | -- | |
Revenue (TTM) YoY Growth | -- | -- | |
Valuation (TTM) | NGNE | None | |
Price/Earnings Ratio | -- | -- | |
Price/Sales Ratio | -- | -- | |
Profitability & Efficiency (TTM) | NGNE | None | |
Net Profit Margin | -- | -- | |
Return on Equity | -- | -- | |
Financial Health (TTM) | NGNE | None | |
Debt/Assets Ratio | -- | -- | |
Assets/Liabilities Ratio | -- | -- | |
Neurogene Inc. Income
Neurogene Inc. Balance Sheet
Neurogene Inc. Cash Flow
Neurogene Inc. Financials Over Time
Analysts Rating
Strong Buy
Buy
Hold
Sell
Strong Sell
Metrics Scores
| Metrics | Score |
|---|---|
| Discounted Cash Flows | Neutral |
| Return on Equity | Strong Sell |
| Return on Assets | Strong Sell |
| Debt/Equity Ratio | Neutral |
| Price/Earnings Ratio | Strong Sell |
| Price/Book Ratio | Buy |
Price Targets
Disclaimer: This 3rd party analysis information is for reference only and does not constitute investment advice.
Historical Market Cap
Shares Outstanding
Neurogene Inc. Executives
| Name | Role |
|---|---|
| Dr. Rachel L. McMinn Ph.D. | Founder, Executive Chair & Chief Executive Officer |
| Ms. Christine Mikail Cvijic J.D. | President & Chief Financial Officer |
| Dr. Julie Jordan M.D. | Chief Medical Officer |
| Dr. Stuart Cobb Ph.D. | Chief Scientific Officer |
| Ms. Donna M. Cochener-Metcalfe J.D. | Senior Vice President, General Counsel & Corporate Secretary |
| Name | Role | Gender | Date of Birth | Pay |
|---|---|---|---|---|
| Dr. Rachel L. McMinn Ph.D. | Founder, Executive Chair & Chief Executive Officer | 1973 | 929.41K | |
| Ms. Christine Mikail Cvijic J.D. | President & Chief Financial Officer | Female | 1978 | 746.75K |
| Dr. Julie Jordan M.D. | Chief Medical Officer | 1972 | 651.04K | |
| Dr. Stuart Cobb Ph.D. | Chief Scientific Officer | 1970 | 478.81K | |
| Ms. Donna M. Cochener-Metcalfe J.D. | Senior Vice President, General Counsel & Corporate Secretary | Female | 1975 | -- |
Neurogene Inc. Insider Trades
| Date | 14 May |
| Name | Cobb Stuart |
| Role | Chief Scientific Officer |
| Transaction | Disposed |
| Type | S-Sale |
| Shares | 6797 |
| Date | 26 Mar |
| Name | Cobb Stuart |
| Role | Chief Scientific Officer |
| Transaction | Acquired |
| Type | A-Award |
| Shares | 7200 |
| Date | 26 Mar |
| Name | Cobb Stuart |
| Role | Chief Scientific Officer |
| Transaction | Acquired |
| Type | A-Award |
| Shares | 42900 |
| Date | 26 Mar |
| Name | Cvijic Christine Mikail |
| Role | President and CFO |
| Transaction | Acquired |
| Type | A-Award |
| Shares | 20300 |
| Date | 26 Mar |
| Name | Cvijic Christine Mikail |
| Role | President and CFO |
| Transaction | Acquired |
| Type | A-Award |
| Shares | 122000 |
| Date | Name | Role | Transaction | Type | Shares |
|---|---|---|---|---|---|
| 14 May | Cobb Stuart | Chief Scientific Officer | Disposed | S-Sale | 6797 |
| 26 Mar | Cobb Stuart | Chief Scientific Officer | Acquired | A-Award | 7200 |
| 26 Mar | Cobb Stuart | Chief Scientific Officer | Acquired | A-Award | 42900 |
| 26 Mar | Cvijic Christine Mikail | President and CFO | Acquired | A-Award | 20300 |
| 26 Mar | Cvijic Christine Mikail | President and CFO | Acquired | A-Award | 122000 |